SEC FORM 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hippel James

(Last)

(First)

(Middle)

614 MCKINLEY PLACE N.E.

(Street)

MINNEAPOLIS

55413

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CFO

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock								12,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	08/15/2022		A		2,728		⁽²⁾	⁽²⁾	Common Stock	2,728	$0	2,728	D
Stock Options (Right to Buy)	$378.08	08/15/2022		A		8,479		⁽²⁾	08/15/2029	Common Stock	8,479	$0	8,479	D
Stock Options (Right to Buy)	$378.08	08/15/2022		A		11,305		⁽³⁾	08/15/2029	Common Stock	11,305	$0	11,305	D
Stock Options (Right to Buy)	$125.05							⁽⁴⁾	08/09/2024	Common Stock	47,389		47,389	D
Stock Options (Right to Buy)	$177.32							⁽⁴⁾	08/08/2025	Common Stock	18,066		18,066	D
Stock Options (Right to Buy)	$177.32							⁽⁴⁾	08/08/2025	Common Stock	24,089		24,089	D
Stock Options (Right to Buy)	$190.41							⁽⁵⁾	08/07/2026	Common Stock	19,936		19,936	D
Stock Options (Right to Buy)	$190.41							⁽⁶⁾	08/07/2026	Common Stock	26,581		26,581	D
Stock Options (Right to Buy)	$267.87							⁽⁷⁾	08/05/2027	Common Stock	14,360		14,360	D
Stock Options (Right to Buy)	$267.87							⁽⁸⁾	08/05/2027	Common Stock	19,147		19,147	D
Stock Options (Right to Buy)	$267.87							⁽⁹⁾	08/05/2027	Common Stock	8,325		8,325	D
Stock Options (Right to Buy)	$267.87							⁽¹⁰⁾	08/05/2027	Common Stock	8,325		8,325	D
Restricted Stock Units	⁽¹⁾							⁽¹¹⁾	⁽¹¹⁾	Common Stock	1,945		1,945	D
Stock Options (Right to Buy)	$481.82							⁽¹¹⁾	08/06/2028	Common Stock	7,600		7,600	D
Stock Options (Right to Buy)	$481.82							⁽¹²⁾	08/06/2028	Common Stock	10,134		10,134	D
Restricted Stock Units	⁽¹⁾							⁽⁷⁾	⁽⁷⁾	Common Stock	3,219		3,219	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.

2. Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

3. Options to purchase 2,826 shares vest on each of 8/15/2023, 8/15/2025 and 8/15/2026 and options to purchase 2,827 shares vest on 8/15/2024.

4. Fully exercisable.

5. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later ate as performance is certified by the Administrator).

6. Options to purchase 6,646 shares vest on 8/7/2020 and options to purchase 6,645 shares vest on each of 8/7/2021, 8/7/22 and 8/7/2023.

7. Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

8. Option to purchase 4,787 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023 and options to purchase 4,786 shares vest on 8/5/2024.

9. Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

10. Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

11. Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

12. Options to purchase 2,534 shares vests on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vests on each of 8/6/2024 and 8/6/2025.

	/s/ Brenda S. Furlow, Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed	08/17/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.